BR112022023334A2 - Imunoglobulina hipersialilada - Google Patents
Imunoglobulina hipersialiladaInfo
- Publication number
- BR112022023334A2 BR112022023334A2 BR112022023334A BR112022023334A BR112022023334A2 BR 112022023334 A2 BR112022023334 A2 BR 112022023334A2 BR 112022023334 A BR112022023334 A BR 112022023334A BR 112022023334 A BR112022023334 A BR 112022023334A BR 112022023334 A2 BR112022023334 A2 BR 112022023334A2
- Authority
- BR
- Brazil
- Prior art keywords
- hypersialylated
- immunoglobulin
- igg
- preparing
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01038—Beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase (2.4.1.38)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063026826P | 2020-05-19 | 2020-05-19 | |
| US202063108741P | 2020-11-02 | 2020-11-02 | |
| PCT/US2021/033150 WO2021236765A1 (en) | 2020-05-19 | 2021-05-19 | Hyper-sialylated immunoglobulin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022023334A2 true BR112022023334A2 (pt) | 2022-12-20 |
Family
ID=78708031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022023334A BR112022023334A2 (pt) | 2020-05-19 | 2021-05-19 | Imunoglobulina hipersialilada |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230192814A1 (https=) |
| EP (1) | EP4153622A4 (https=) |
| JP (1) | JP7835691B2 (https=) |
| KR (1) | KR20230012576A (https=) |
| CN (1) | CN115867571A (https=) |
| AU (1) | AU2021275115A1 (https=) |
| BR (1) | BR112022023334A2 (https=) |
| CA (1) | CA3182136A1 (https=) |
| CO (1) | CO2022016670A2 (https=) |
| MX (1) | MX2022014525A (https=) |
| WO (1) | WO2021236765A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2877589B1 (en) | 2012-07-26 | 2024-03-06 | Momenta Pharmaceuticals, Inc. | Glycoproteins with anti-inflammatory properties |
| WO2014186310A1 (en) | 2013-05-13 | 2014-11-20 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
| CA3174533A1 (en) * | 2020-03-05 | 2021-09-10 | Momenta Pharmaceuticals, Inc. | Methods of making hyper-sialylated immunoglobulin |
| WO2026014960A1 (ko) * | 2024-07-11 | 2026-01-15 | 건국대학교 산학협력단 | 인간으로부터 분리한 형질세포들을 이용한 α-2,6-시알산화 면역글로불린의 제조방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101613705A (zh) * | 2002-03-19 | 2009-12-30 | 国际植物研究所 | 在植物中优化聚糖生成 |
| ES2805964T3 (es) * | 2008-10-29 | 2021-02-16 | Janssen Biotech Inc | Composiciones de galactosa alfa (1-3) galactosa |
| ES2802274T3 (es) | 2013-05-02 | 2021-01-18 | Momenta Pharmaceuticals Inc | Glicoproteínas sialiladas |
| EP2821482A1 (en) * | 2013-07-05 | 2015-01-07 | Roche Diagniostics GmbH | N-terminally truncated glycosyltransferases |
| JP6931058B2 (ja) * | 2016-12-21 | 2021-09-01 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗体のインビトロ糖鎖工学における酵素の再使用 |
| US20210353752A1 (en) * | 2018-10-11 | 2021-11-18 | Momenta Pharmaceuticals, Inc. | Treatment with highly silylated igg compositions |
| JP7398002B2 (ja) | 2020-02-14 | 2023-12-13 | 北京小米移動軟件有限公司 | フィードバック方式の指示及び決定方法、装置、記憶媒体 |
| KR20230012560A (ko) | 2020-05-19 | 2023-01-26 | 모멘타 파머슈티컬스 인코포레이티드 | 과시알화된 IgG의 제조 및 정제 |
| JP2023538400A (ja) * | 2020-08-21 | 2023-09-07 | モメンタ ファーマシューティカルズ インコーポレイテッド | 高シアル化免疫グロブリン |
-
2021
- 2021-05-19 BR BR112022023334A patent/BR112022023334A2/pt unknown
- 2021-05-19 EP EP21809062.9A patent/EP4153622A4/en active Pending
- 2021-05-19 CA CA3182136A patent/CA3182136A1/en active Pending
- 2021-05-19 US US17/925,999 patent/US20230192814A1/en active Pending
- 2021-05-19 WO PCT/US2021/033150 patent/WO2021236765A1/en not_active Ceased
- 2021-05-19 MX MX2022014525A patent/MX2022014525A/es unknown
- 2021-05-19 CN CN202180036166.7A patent/CN115867571A/zh active Pending
- 2021-05-19 JP JP2022570510A patent/JP7835691B2/ja active Active
- 2021-05-19 KR KR1020227044192A patent/KR20230012576A/ko active Pending
- 2021-05-19 AU AU2021275115A patent/AU2021275115A1/en active Pending
-
2022
- 2022-11-19 CO CONC2022/0016670A patent/CO2022016670A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2022016670A2 (es) | 2022-11-29 |
| US20230192814A1 (en) | 2023-06-22 |
| CN115867571A (zh) | 2023-03-28 |
| KR20230012576A (ko) | 2023-01-26 |
| CA3182136A1 (en) | 2021-11-25 |
| AU2021275115A1 (en) | 2022-11-10 |
| WO2021236765A1 (en) | 2021-11-25 |
| JP2023526421A (ja) | 2023-06-21 |
| MX2022014525A (es) | 2022-12-13 |
| EP4153622A4 (en) | 2024-06-12 |
| JP7835691B2 (ja) | 2026-03-25 |
| EP4153622A1 (en) | 2023-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022023334A2 (pt) | Imunoglobulina hipersialilada | |
| CL2021000630A1 (es) | Métodos para producir un anticuerpo anti-c5 (divisional de la solicitud no. 201701585) | |
| CL2023001092A1 (es) | Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor | |
| CL2019002268S1 (es) | Conjunto de abrazadera de bastidor para automóvil. | |
| MX2019008146A (es) | Virus alterado. | |
| BR112017023943A2 (pt) | anticorpos heterodimêricos que ligam cd3 e antígenos de tumor | |
| CY1121944T1 (el) | Σταθεροποιημενες πρωτεϊνες για ανοσοποιηση εναντι staphylococcus aureus | |
| MX2018015592A (es) | Anticuerpos inhibidores de puntos de control biespecificos. | |
| MX2017006966A (es) | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales. | |
| CL2021002331A1 (es) | Formulaciones de anticuerpo anti-il-36r | |
| BR112021011529A2 (pt) | Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado | |
| IL276211A (en) | HU14.18K322A monoclonal antibody production process | |
| MX2019000271A (es) | Anticuerpos humanizados que transmigran a traves de la barrera hematoencefalica y usos de los mismos. | |
| JOP20200295A1 (ar) | أجسام أحادية النوعية ومتعددة النوعية مضادة لـ tmeff2 المضاد واستخداماتها | |
| HUE061078T2 (hu) | PSMA elleni humanizált ellenanyagok | |
| CY1122728T1 (el) | Αντισωματα εναντι hpa-1a | |
| CO2018010286A2 (es) | Método para la purificación de proteínas | |
| EP4001306C0 (en) | HUMANIZED MONOCLONAL ANTIBODIES AGAINST VEGF | |
| ECSP20024551A (es) | ANTICUERPO MONOCLONAL PARA IL-5Ra | |
| EP3906261A4 (en) | HUMANIZED AND AFFINITY MATURED ANTI-CEACAM1 ANTIBODIES | |
| EP4163301C0 (en) | Humanized Anti-GPC-1 Antibody | |
| CL2021001104A1 (es) | Anticuerpo monoclonal que se une específicamente al antígeno cd20 | |
| EP3891180C0 (en) | HUMANIZED ANTIBODIES AGAINST IL17BR | |
| IL290825A (en) | Methods of producing antibody compositions | |
| CL2022001033A1 (es) | Método para preparar aril 2-tetrazol-2-il cetona con selectividad mejorada |